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Introduction. HIV-1 is often acquired in the presence of pre-existing co-infections, such as Herpes Simplex Virus 2 (HSV-2). We
examined the impact of HSV-2 status at the time of HIV-1 acquisition for its impact on subsequent clinical course, and total
CD4+ T cell phenotypes. Methods. We assessed the relationship of HSV-1/HSV-2 co-infection status on CD4+ T cell counts and
HIV-1 RNA levels over time prior in a cohort of 186 treatment naı¨ve adults identified during early HIV-1 infection. We assessed
the activation and differentiation state of total CD4+ T cells at study entry by HSV-2 status. Results. Of 186 recently HIV-1
infected persons, 101 (54 %) were sero-positive for HSV-2. There was no difference in initial CD8+ T cell count, or differences
between the groups for age, gender, or race based on HSV-2 status. Persons with HIV-1/HSV-2 co-infection sustained higher
CD4+ T cell counts over time (+69 cells/ul greater (SD=33.7, p = 0.04) than those with HIV-1 infection alone (Figure 1), after
adjustment for HIV-1 RNA levels (257 cells per 1 log10 higher HIV-1 RNA, p,0.0001). We did not observe a relationship
between HSV-2 infection status with plasma HIV-1 RNA levels over time. HSV-2 acquistion after HIV-1 acquisition had no
impact on CD4+ count or viral load. We did not detect differences in CD4+ T cell activation or differentiation state by HSV-2+
status. Discussion. We observed no effect of HSV-2 status on viral load. However, we did observe that treatment naı¨ve,
recently HIV-1 infected adults co-infected with HSV-2+ at the time of HIV-1 acquisition had higher CD4+ T cell counts over time.
If verified in other cohorts, this result poses a striking paradox, and its public health implications are not immediately clear.
Citation: Barbour JD, Sauer MM, Sharp ER, Garrison KE, Long BR, et al (2007) HIV-1/HSV-2 Co-Infected Adults in Early HIV-1 Infection Have Elevated
CD4+ T Cell Counts. PLoS ONE 2(10): e1080. doi:10.1371/journal.pone.0001080
INTRODUCTION
HIV-1 is often acquired in the presence of pre-existing co-infections,
such as Herpes Simplex Virus 2 (HSV-2). The effects of co-infection
on clinical course of HIV-1 infection may be complex and vary by
the co-infecting agent. Many reports suggest an increase in the risk of
HIV-1 transmission to HSV-2 infected individuals, reviewed in [1],
with recent reports suggesting possible molecular mechanisms [2].
HSV infection has been shown to increase HIV-1 replication in
some studies [3], but has shown no association in other studies [4].
The impact of HSV-2 infection on the human immune system and
its ability to counter other infections such as HIV-1 may be complex
[5]. HSV-2 infection alters the function and phenotype of monocytes
[6–8], impeding their maturation, which may in turn alter the
phenotype and function of interacting CD4+ and CD8+ T cells.
HSV-2 is a ligand for certain TLR molecules [9], and may mediate
the effect on dendritic cells. HSV-2 may alter the innate immune
system, with subsequent impacts on the adaptive immune system.
We examined the impact of HSV-2 status at the time of HIV-1
acquisition on subsequent clinical course. In agreement with others,
and in contrast to several other groups [3,10], we observed no effect
of HSV-2 status on viral load [4]. We observed that treatment naı¨ve,
recently HIV-1 infected adults co-infected with HSV-2+ at the time
of HIV-1 acquisition had higher CD4+ T cell counts over time. This
effect was independent of viral load and other common co-infections.
These results suggest a pre-existing HSV-2 infection may directly
modulate the CD4+ T cell population during early HIV-1 disease,
with possible beneficial effects on clinical outcomes.
METHODS
Cohort and Laboratory Measures
We examined CD4+ and CD8+ T cell counts, plasma HIV-1 RNA
levels in a cohort of 186 treatment naı¨ve adults identified during
early HIV-1 infection (study entry within 170 days of HIV-1
seroconversion) by STARHS [11]. These individuals were enrolled
and followed at the Federal University of Sao Paulo, Brazil, and
removed from the analysis at the time they started anti-retroviral
therapy or were lost to follow-up. HIV-1 subtypes were pre-
dominantly B and F, with some circulating recombinant forms [12].
We collected information on participant age, gender, race and
CCR5 delta32 genotype. In addition, we determined Hepatitis B,
GBV-C and HSV-2 co-infection serology by indirect ELISA assays
(GBV-C ELISA, provided by Dietmar Zdunek, Roche Diagnostics,
Germany; HSV-2 ELISA. Dia Sorin, Saluggia, Italy). We employed
Diasorin ‘Method 2’ which is an ELISA based method with high
sensitivity to detect primary, secondary and recurrent HSV-2
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infections but has lowered specificity [13]. We assessed the activation
state (CCR5 percent and CD38 percent or MFI, both by Parmingen,
San Diego, CA) and the differentiation state (CCR7, CD25, CD28
and CD27, all from BD Biosystems, San Jose, CA) of total CD4+ T
cells by four color flow cytometric panels in a FACSCalibur (BD
Biosystems), followed by analysis using Cell Quest software (BD). We
did not detect differences in T cell activation state, nor differentiation
state of total CD4+ T cells by HSV-2+ status. Ethical approval was
obtained from the Federal University of Sao Paulo IRB and patients
gave informed consent.
Statistical Analysis
As is standard clinical practice in Brazil, subjects are not started on
antiretroviral drug therapy until CD4+ T cell counts have
decreased to 350 CD4+ T cells/ml or below, or is otherwise
clinically indicated. In this study, we right censored (removed from
analysis) subjects at the time they initiated antiretroviral therapy,
which was initiated when CD4+ T cells fell bellow 300 cells/ml.
We used longitudinal mixed effects models to assess the relation-
ship of co-infection status on CD4+ T cell counts and HIV-1 RNA
levels, with random effects for time and intercept. We used the Chi
Square or Fisher’s Exact to test differences in proportions between
the two groups by HSV-2 status, and the Wilcoxon Two Sample
Test to compare differences in continuous variables at study entry.
All analyses were performed in SAS 9.2 for Windows XP.
RESULTS
Of 186 recently HIV-1 infected persons, 101 (54 %) were sero-
positive for HSV-2, and the balance tested negative. A full
description of the cohort at study entry status may be found in
Table 1. There was no difference between the groups for age,
gender, race, or CCR5 delta32 genotype based on HSV-2 status.
Table 1. Clinical and Demographic Characteristics of the
Study Cohort At Study Entry.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Measure Median IQR N
Log10 HIV-1 RNA c/mL 4.3 (3.6, 4.9) 177
CD4+ T cell counts/uL 535 (409, 698) 184
Age (Years) 30.8 (24.7, 36.3) 186
Clinical Follow-Up
Observation Time (Days) 389 (117, 833) 186
Total Person Days (Sum) 96466 186
Time Until ART Started (Days)* 381 (129.5, 649) 49
Measure Frequency Number
HSV-2+ Serostatus 54% 101/186
HCV Serostatus 2% 2/115
HBV Serostatus* 39% 45/117
Demographics
Male Gender 92% 168/186
Ethnicity
Asian 1% 2
White 60% 113
Mulato 19% 34
Black 8% 14
Other 12% 22
Brazilian Amerindian 0.5 % 1
*Anti Hepatitis B Core Antibody.
doi:10.1371/journal.pone.0001080.t001..
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Figure 1. Higher absolute CD4+ T cell counts in HSV-2+/HIV-1+ subjects independent of HIV-1 viral load. The open blue diamonds represent the
CD4+ T cell counts, and the open red dots represent HIV-1 viral load over time for persons co-infected with HSV-2 at the time of diagnosis with an
early HIV-1 infection. The solid blue diamonds represent the CD4+ T cell counts, and the solid red dots HIV-1 viral load, for those HSV-2 negative at
the time of early HIV-1 infection. Observations were right censored at the time anti-retroviral therapy was initiated, which occurred at approximately
a CD4+ T cell count of 350 cells/mL.
doi:10.1371/journal.pone.0001080.g001
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In a longitudinal mixed effects regression model, we observed
that persons with HIV-1/HSV-2 co-infection sustained higher
CD4+ T cell counts over time (average of 69 cells/ml greater
(SD = 33.7, p = 0.04)) than those with HIV-1 infection alone
(Fig. 1), after adjustment for HIV-1 RNA levels (257 cells per 1
log10 higher HIV-1 RNA, p,0.0001). We did not observe
a relationship of HSV-2 infection status with plasma HIV-1
RNA levels over time (Fig. 1).
HSV-2 co-infection was associated with positive Hepatitis B
core antigen serostatus (Chi Square, p = 0.02). In a statistical
model adjusted for hepatitis B core antigen serostatus as well as
viral load, HSV-2+ status tended to associate with higher CD4+ T
cell counts over time (89 cells higher for HSV2+, p = 0.07), while
hepatitis B serostatus did not (69 cells higher for anti-HBc+,
p = 0.16). This result suggests the association of HSV-2 status with
CD4+ T cell counts is independent of viral load and hepatitis B
core antigen serostatus, but does not rule out the possibility that
HBV infection (either active infection or cleared infection) may
also be associated with higher CD4+ T cell counts in early HIV
disease. Likewise, the association of HBV with CD4+ T cell counts
may be driven in part or entirely via its association with HSV-2+.
Unlike HSV-2, which is a persistent infection in humans,
hepatitis B may be cleared. Hepatitis B core antigen status reflects
exposure and may not indicate active infection. Hence, anti-
hepatitis B core antigen status likely reflects higher net exposure to
sexually transmitted agents, as is reflected in the association of
anti-HBc+ correlation with HSV-2 infection. We also examined
the rate of positive GBV-C serostatus, and found it was slightly
higher in the HSV-2+ than HSV-2– HIV-1 infected groups (27%
versus 25%). This difference was not significant and we found no
association with CD4+ T cell count or viral load by GBV-C status.
We did not detect an association between study entry HSV-2
status and time to initiation of anti-retroviral therapy. However, as
only 48 of the 186 enrolled initiated ART during our period of
observation we may have been underpowered to observe such an
effect should it exist.
Incident HSV-2 Infection, CD4+ T cell counts, and
HIV-1 RNA Level
We measured HSV-2 status after one year of follow-up in a set of
53 persons who had tested negative at study entry. Of 53 persons
tested, 47 had sufficient clinical follow-up to allow evaluation of
HSV-2 test results on subsequent CD4+ and viral load levels. Of
these 47, 10 (21.2 %) had seroconverted to HSV-2+ status since
acquiring HIV-1 and entering the cohort. We found that the
acquisition of HSV-2 after infection HIV-1 was not associated
with subsequent changes in viral load or with CD4+ T cell count
during the untreated time period (Fig. 2).
CD4+ T cell Phenotype and HSV-2+ Status
Among 34 recently HIV-1 infected persons, we compared 14
persons HSV-2+ at study entry with 20 HSV-2- persons for
differences in total CD4+ T cell phenotype, including activation
markers, and differentiation markers (Fig. 3). We observed no
difference in the activation state of CD4+ T cells by HSV2+ status,
or with the differentiation status of CD4+ T cells.
DISCUSSION
We found that HIV-1/HSV-2 co-infected treatment naı¨ve adults
in early HIV-1 infection had higher CD4+ T cell counts than
those infected with HIV-1 alone. This effect may be due to the
effects of a pre-existing HSV-2 infection on the immune system,
a dynamic which may remain in place after acquisition of HIV-1.
The association of HSV-2 with higher susceptibility to HIV-1
Figure 2. HSV-2 acquisition after HIV-1 acquisition is not associated with subsequent differences in CD4+ T cell counts or HIV-1 viral load. The
open blue diamonds represent the CD4+ T cell counts, and the open red dots represent HIV-1 viral load, over time for persons testing positive for
HSV-2 at 1 year after study enrollment. The solid blue diamonds represent the CD4+ T cell counts, and the solid red dots HIV-1 viral load, for those
HSV-2 negative at 1 year after study enrollment. Forty-seven of the 85 persons who tested HSV-2 negative at study entry were re-tested. Observations
were right censored at the time persons initiated anti-retroviral therapy, which was initiated at approximately a CD4+ T cell count of 350 cells/mL.
doi:10.1371/journal.pone.0001080.g002
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infection may be attributable to higher CD4+ T cell counts in
circulation and in turn with higher target cell availability for HIV-
1 in sites of entry. This effect of HSV-2 on CD4+ T cell counts
may further heighten risk of infection beyond the increased
opportunity for HIV-1 viral entry through genital lesions caused
by HSV-2.
Incident HSV-2 infection – that is seroconversion or acquisition of
HSV-2 after infection HIV-1 – was observed in our cohort, and
analyzed separately for its effect on viral load and CD4+ T cell
count. We did not detect subsequent changes in the CD4+ or viral
load among a subset of this cohort who were observed for acquisition
HSV-2 subsequent to HIV-1 infection. That an incident HSV-2
infection did not modulate the relationship of HIV-1 to viral load or
CD4+ T cell count suggests that the effect of HSV-2 infection on
CD4+ T cell counts manifests prior to acquisition of HIV-1.
The manner by which HSV-2 co-infection may confer a pro-
tective effect on CD4+ T cell populations is not clear. To explore
a link between HSV-2 infection and changes in T cell
differentiation we gauged the differentiation stage of total CD4+
T cells. We detected no expansion of any CD4+ T cell
differentiation subset between HSV-2+ and HSV-2- persons.
HSV-2 may stimulate cytokines which promote new CD4+ T cell
production, decrease the rate of CD4+ activation induced T cell
destruction or potentially increase CD4+ T cell survival [14–17].
Recent evidence suggests that herpesvirus may have broad
immunomodulatory effects. In a murine model of gammaherpes-
virus (cHV68) infection, latent infection was associated with
elevated levels of serum IFN-c and TNF-a, and protected mice
from infection by two distinct bacterial strains [18]. Herpesvirus
infection may have a protective effect against other infections by
establishing a level of innate immunity that is maintained as the
host tries to prevent HSV-2 emergence from latency.
Herpes virus infections, which are highly prevalent among
humans, may not be solely pathogenic, and may in fact impart
some immunologic benefit to the host [18]. More recent results
from our group (Long et al, Submitted 2007) indicate that HSV-2
infection has pan-leukocytic effects, with general increases in both
CD4+ and CD8+ T cell counts as well as Natural Killer (NK) cell
counts. Additional results from this same study suggest HSV-2
infection may distract or decoy NK cells from targeting HIV-1.
Clinical pathology from HSV-2 infection is only observed in
a fraction of those with HSV-2. However the burden of disease
from HSV-2 and other herpesviruses (EBV, HHV-8, Zoster) is
significant worldwide. The theory of HSV-2 viral adaptation
conferring benefit to the host must be approached with caution.
Our study is subject to several limitations. Our method for
detection of HSV-2 infection is of high sensitivity, indicating a very
low false negative rate. However, our method has lower specificity,
indicating some individuals counted as HSV-2 infected here may
in fact not be carriers. There is continuing debate over the optimal
method for detection of HSV-2 status – ELISA based methods
such as ours are rapid and highly sensitive but do not match the
precision and accuracy of the western blot [13]. The higher false
positive rate translates to a conservative bias. That is – the effects
of HSV-2 on higher CD4+ counts seen here - are likely diluted,
not amplified, by the inclusion of HSV-2 negative persons. Hence,
the difference in CD4+ T cell counts by HSV-2 status may in fact
be larger than reported here. In addition there may exist a modest
difference in viral load in early infection which we did not detect.
There is a growing body of research on the role of HSV-2 in the
risk acquisition of HIV-1 [19,20]. A recent study by Nagot et al. has
demonstrated that daily valacyclovir to suppress HSV-2 replication
was associated with reductions in genital and plasma HIV-1 RNA
levels [3]. Our study differs from that of Nagot et al. in several ways.
In our cohort we 1) studied persons identified in very early HIV-1
infection, 2) our study was mostly men (90 %) compared to the Nagot
trial which was all female, and 3) valacyclovir was not used to control
re-activations of HSV-2 disease (its use in Brazil is uncommon due to
expense). Thus our findings represent the impact of the natural
history of HSV-2 serostatus on HIV-1 disease markers. Gender may
Figure 3. No Difference in Total CD4+ T Cell Phenotypes by HSV-2 Status. Red symbolizes those persons who test positive for HSV-2 at study entry
and are HIV-1 co-infected. Green are those persons who tested negative for HSV-2 at study entry and are infected with HIV-1 only. ‘27’ represents
CD27, and ‘RA’ represents CD45RA, which were used to define differentiation stages of the total CD4+ T cell pool.
doi:10.1371/journal.pone.0001080.g003
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play an important role in modulating the relationship of HSV-2 to
immune status during HIV-1 infection. Indeed, results from HSV-2
subunit vaccine trials have indicated that subunit vaccines are
immunogenic and confer protection among women, but not men
[21]. The basis for the role of gender in modulating this response is
not clear but may at least partially explain differences between
studies discussed here.
Worldwide, HSV-2 is a common infection in adults [22], and
among persons with HIV-1 or at risk for HIV-1 infection the
prevalence of HSV-2 may be greater than 50 %. Having HSV-2 at
the time of HIV-1 acquisition appears to have no effect on plasma
viral load during early infection, yet may be associated with higher
CD4+ T cell counts. HSV-2 acquisition after acquisition of HIV-1
was not associated with subsequent differences in CD4+ T cell
counts or HIV-1 RNA level. This suggests the order in which
HSV-2 and HIV-1 are acquired may influence the nature of HSV-
2 impact on the immune system.
Hence, the same viral co-infection which may increase
susceptibility to HIV-1 infection due to chronic mucosal tissue
inflammation and or ulceration may in turn be associated with
higher CD4+ T cell counts after acquisition of HIV-1. This is
a striking paradox, and its public health implications are not
immediately clear. It will be of interest to determine if other
cohorts of recently infected adults display a similar relationship of
HSV-2 co-infection with elevated CD4+ T cell counts over time.
Such an association may have been overlooked in favor of
examination of an association with viral load. Recent reports have
suggested that HIV-1 viral load accounts for a relatively small
share of the rate of CD4+ T cell loss in HIV disease [23]. HSV-2
co-infection may account for some of the variation in that
relationship by boosting CD4+ T cell counts in early infection, in
a manner independent of viral load.
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